Cereno Scientific receives regulatory approval to start clinical study with its drug candidate CS1

Cereno Scientific (Aktietorget: “CRNO B”) announced today that the company has received approval from the Medical Products Agency (‘Läkemedelsverket’) and the Ethical Review Board (‘Etikprövningsnämnden’) in Uppsala, Sweden, to initiate the first clinical study of its drug candidate, CS1.

The approval from the Medical Products Agency and the Ethical Review Board is the starting signal for a first clinical study with the drug candidate CS1, which Cereno Scientific has developed.
The study will assess the safety and tolerability, as well as the pharmacokinetics of CS1 in adults with borderline hypertension and obesity. The study will also investigate the efficacy of CS1 on biomarkers related to risk for thrombosis-related complications.

Thrombosis is the biggest cause of death in the world. Cereno Scientific aims to bring to market a new preventive medicine to treat thrombosis-related disease, offering an opportunity for more effective treatment while lowering the risk of major bleeding complications associated with current treatment with blood-thinning drugs.

The therapeutic potential of CS1 as a new treatment for the prevention of thrombosis has been demonstrated in preclinical studies. These studies have shown that it is possible to reduce thrombosis formation by stimulating the body’s own defence system against thrombosis, with no increased bleeding.

Cereno Scientific's CEO, Sten R Sörensen, commented:

“This is a significant milestone for Cereno Scientific. It is a major achievement for our team and partners who have all worked so diligently in pursuit of our ambition to bring a much needed, new approach to benefit patients suffering from thrombosis-related disease.” 

For more information, please contact:
Sten R. Sörensen – Chief Executive Officer
Telephone: +46 73 374 03 74.
Email: sten.sorensen@cerenoscientific.com

This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact person set out above, on October 2, 2017. 

About Cereno Scientific AB 
Cereno Scientific develops preventive medicines to treat thrombosis-related disease, such as myocardial infarction and stroke. These novel therapeutics stimulate the body's own intelligent clot-busting system, and are being developed to treat thrombosis-related cardiovascular diseases on the global market. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn leads to a high risk of new blood clots. The benefit with Cereno Scientific's drug candidate, CS1, is an improved balance between preventing blood clots and treatment-related side effects - leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. CS1 has a unique mechanism of action, a potentially wide range of indication opportunities connected to large blood clot-related diseases and, consequently, a large market potential. The Göteborg-based company is listed on the AktieTorget stock market, conducts research activities at AstraZeneca's BioVentureHub in Göteborg and is supported by GU Ventures. For more information, see www.cerenoscientific.se.


Documents & Links